Pricing Log in Create free account
Friday 6 November 2026 Export PEN’s income statement to Excel — free account

Penumbra, Inc.

PEN Healthcare Medical Devices

Penumbra, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 17.5% from fiscal 2024.

Revenue
+15.6%
EPS
−8.29%
Free cash flow
−37.2%
Total debt
−10.3%

Quarter to September 2026, against a year earlier

319.96 1.15 −0.36%
Market cap
$12.7B
P/E
80.3×
Fwd P/E
68.7×
Dividend yield
—
F-score
8/9
Altman Z
20.17
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Penumbra, Inc. (PEN) SEC filings, changes and red flags

Red flags

No red flags have been raised by Penumbra, Inc.’s filings on file.

Filings

Form Period Filed What it reports Flags
10-Q Sep 30, 2026 P1I2: 18 modified
P2I1A: no material changes, the filing says
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jun 18, 2026 5.07 Submission of matters to a vote of security holders
8-K May 6, 2026 5.07 Submission of matters to a vote of security holders
10-Q Mar 31, 2026
8-K May 6, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2025 1: 5 added · 1 removed · 41 modified
1A: 16 added · 3 removed · 73 modified
7: 4 added · 10 removed · 32 modified
8-K Feb 25, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 14, 2026 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Sep 30, 2025
8-K Nov 5, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Aug 22, 2025 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Jul 29, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Mar 31, 2025
8-K Apr 23, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 18, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 30, 2024
8-K Oct 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 30, 2024
8-K Jul 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 7, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 22, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.